| Background and ObjectiveIn China, gastroenteric cancer is one of the most common malignant tumor. Variousclinical meta show that the work of the last decade of its early diagnosis and earlytreatment has been great progress. For partial loss of radical surgery opportunity cases,currently that is the use of chemotherapy, radiation therapy, interventional therapy,biological therapy and other measures. But, traditional means of radiotherapy andchemotherapy is ineffective with serious side effects. So, the invention of a new route ofadministration and new formulations is critical. The research about targeted cancer therapytechnology can greatly improve the therapeutic effect and effectively reduce drug sideeffects of chemotherapy cancer treatment has opened up a new way of cancer treatment. So,this paper discusses the short-term therapeutic efficacy and side effect of endoscopicimplantation with chemotherapeutic slow-release ion for advanced gastroenteric tumor.MethodsThe clinical data of37patients with gastroenteric tumor, from April2006to October2012in Jinan Fourth People’s Hospital of endoscopic implantation of chemotherapeuticslow-release ion, were retrospectively analyzed. Endoscopic5-FU sustained releaseparticles were implanted into the tumor site. A week later, To assess the side effects andclinical efficacy, according to the review of liver and kidney function, blood, the symptomsof patients.1-2months after surgery, to assess lesions localized changes, according to thereview of Digestive Endoscopy. All patients after implantation only give symptomatic andsupportive treatment, not for any other treatment of the tumor line.Results1. Clinical obstructive symptoms with varying degrees of ease, the total effective rateof86.96%; pain relief in27cases, accounting for73.0%; weight gain in22cases, accounting for about59.5%.2. According to the WHO evaluation criteria,6patients with esophageal cancer, CR0,PR1, SD4cases, the effective rate of83.3%; nine cases of gastric cardia cancer, CR0, PR1, SD6, efficiency of77.8%;12patients with gastric cancer, CR0, PR4, SD for the fivecases, the effective rate of75.0%;5cases of colorectal cancer, CR0, PR1, SD2cases theeffective rate was60.0%. The average effective rate was75.0%.3. Lesion sites have a small amount of bleeding in the operation. Intraoperative andpostoperative perforation, bleeding, serious infections and other complications did notoccur. One patient upper abdominal discomfort, one patient developed nausea andvomiting, one patients with mild leukocyte reduction. There were four cases of mildabnormal liver function, but no significant change compared with before treatment.Conclusion1. The therapy of endoscopic implantation with chemotherapeutic slow-release ioncan significantly improve patients vomiting, fullness after eating, and other symptoms ofgastrointestinal obstruction, can increase food intake in patients, can Relieve abdominalpain, increase weight, and so on.To improve the patient’s quality of life.2. The therapy of endoscopic implantation with chemotherapeutic slow-release ioncan shrink tumors entity or slow down its growth rate in various degree.3. Adverse reactions and complications compared with systemic chemotherapysignificantly reduced. In addition to the small number of patients with only mildgastrointestinal reactions, there were not the apparent liver and kidney dysfunction, bonemarrow suppression, white blood cell count decreased.4. The therapy has easy to operate, less trauma, less pain, adverse reactionsis andworthy of further promotion and application. |
